Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: vaccination

Tofacitinib After Live Shingles Vaccination Does Not Impair Immunogenicity

Reuters Staff  |  August 29, 2017

NEW YORK (Reuters Health)—Tofacitinib begun two to three weeks after live zoster vaccination does not impair immunogenicity, and vaccination appears to be safe in patients with pre-existing varicella zoster virus (VZV) immunity, researchers report. Patients with rheumatoid arthritis (RA) are about twice as likely as healthy adults to develop herpes zoster, or shingles, and the…

Filed under:ConditionsResearch RheumRheumatoid Arthritis Tagged with:Arthritis & RheumatologyshinglesTofacitinibvaccinevaricella zoster virus

Shingles Vaccination Not at Goal Levels for U.S. Seniors

Madeline Kennedy  |  November 28, 2016

(Reuters Health)—Just one in five people over age 60 in the U.S. have been vaccinated against a painful eruption of herpes zoster (shingles), despite recommendations that all of them should get the shot. It’s estimated that among people over age 50, one in three will eventually develop shingles. After age 80, half of adults have…

Filed under:Conditions Tagged with:CDCelderlyherpes zostershinglesvaccinationvaccine

Ethics Forum: Pediatric Vaccination Refusals Raise Challenges for Physicians

Emily von Scheven, MD, MAS  |  April 13, 2016

The boy who could not walk: S.L. is a previously healthy 10-year-old boy who has not walked for three months. Physical examination reveals swollen wrists, knees, ankles and several toes. There is reduced hip range of motion and flexion contractures of both knees. He can stand with assistance, but is unable to take a single…

Filed under:ConditionsEthicsPediatric ConditionsPractice SupportProfessional Topics Tagged with:autismdeclineEthicsPatientsPediatricPhysiciansRheumatic Diseaserheumatologistvaccination

Project Increases Pneumococcal Vaccination Rates in Rheumatology Patients

Will Boggs, MD  |  August 26, 2015

NEW YORK (Reuters Health)—A multicomponent intervention can significantly increase pneumococcal vaccination rates in pediatric rheumatology patients, researchers report. “The interventions outlined in our article can easily be implemented in pediatric rheumatology practices or other subspecialty clinics,” Dr. Julia G. Harris from Children’s Mercy Hospital, Kansas City, Mo., told Reuters Health by email. “It takes additional…

Filed under:ConditionsOther Rheumatic Conditions Tagged with:Pediatric Rheumatologypneumococcal vaccinevaccination

Vaccinations for Immunocompromised Patients Are Shared Responsibility of Specialists, Primary Care Physicians

Kathy Holliman  |  September 1, 2014

Infectious Diseases Society of America recommends both physician groups educate patients, household members on importance of vaccines

Filed under:Biologics/DMARDsClinical Criteria/GuidelinesConditionsDrug Updates Tagged with:AC&RAmerican College of Rheumatology (ACR)BiologicsdrugGuidelinesHollimanimmunocompromisedMethotrexatepatient carerheumatologistSafetyvaccination

Rheuminations: The Humble Case Report Tells a Story

Bharat Kumar, MD, MME, FACP, FAAAAI, RhMSUS  |  April 4, 2025

I often think about medical literature as a sprawling metropolis. There are towering skyscrapers of randomized controlled trials, lofty schools of systematic reviews and meta-analyses, and verdant parks of qualitative studies. Much less assuming are the case reports, which are sort of like homesteads for the majority of people who publish and contribute to the…

Filed under:OpinionRheuminations Tagged with:case reportimage case report

State Legislative Update, Spring 2025

Joseph Cantrell, JD  |  March 24, 2025

With the state legislative session in full swing, the ACR is currently tracking 114 pieces of state legislation across many issue areas, including utilization management, prescription drug review boards and vaccines.

Filed under:Legislation & AdvocacyPractice Support Tagged with:ACR advocacyloan forgivenessPDABstate legislationvaccinationvaccines

Under Pressure: Understanding Dysautonomia & POTS

Jason Liebowitz, MD, FACR  |  January 1, 2025

Brit Adler, MD, provided a detailed analysis into the symptoms and management of patients with postural orthostatic tachycardia syndrome.

Filed under:ConditionsEULAR/OtherMeeting Reports Tagged with:autonomic nervous systemDysautonomiapostural orthostatic tachycardia syndrome (POTS)

Top Research in Rheumatoid Arthritis Presented at ACR Convergence 2024

Jeffrey Curtis, MD, MS, MPH  |  December 3, 2024

Why this research is relevant to clinicians today & researchers in the future WASHINGTON, D.C.—The ACR Convergence 2024 meeting in Washington, D.C., reflected the continued advancement of science and practical research in the field of rheumatoid arthritis. Highlights this year centered on new RA treatments and new uses of existing treatments; the use of artificial…

Filed under:ACR ConvergenceConditionsGuidanceMeeting ReportsRheumatoid Arthritis Tagged with:ACR Convergence 2024ACR Convergence 2024 RA

Unless Congress Acts, Medicare Reimbursement Will Remain Flat or Drop in 2025

From the College  |  November 12, 2024

The 2025 Medicare Physician Fee Schedule final rule, released Nov. 1, includes a conversion factor of $32.3465, a 2.83% drop from 2024. In response to advocacy efforts from the ACR and other medical societies, Congress recently introduced the Medicare Patient Access and Practice Stabilization Act of 2024, which would eliminate the 2.83% payment cut and provide an inflationary update for 2025 equal to 50% of the Medicare Economic Index.

Filed under:Billing/CodingLegislation & Advocacy Tagged with:ACR advocacyMedicare Physician Fee Schedule (MPFS)Medicare Reimbursement

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 24
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences